Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Fabio Puglisi(University of Udine), Maria Rosaria Valerio(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Giulia Bianchi, Diletta Valsecchi(Novartis (Italy)), Michele Orditura(University of Campania "Luigi Vanvitelli"), Daniela Castelletti(Novartis (Italy)), Filippo Montemurro(Roche (Switzerland)), Alberto Zambelli, Ida Paris(Agostino Gemelli University Polyclinic), Nicola Battelli(Ospedale di Macerata), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Ettore Cotroneo, Giampaolo Bianchini(Vita-Salute San Raffaele University), Marco Colleoni(European Institute of Oncology), Vincenzo Adamo(University of Messina), Mario Giuliano(Regione Campania), Donatella Grasso(Novartis (Italy)), Lucia Del Mastro(Ospedale Policlinico San Martino), Valentina Guarnieri(University of Padua), Sara Bianchetti(Novartis (Italy)), Giacomo Allegrini, Luca Malorni(Azienda Usl Toscana Centro), Laura Amaducci(Ospedale degli Infermi), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Saverio Cinieri(Ospedale A. Perrino)
Cancer Research
February 15, 2020
10.1158/1538-7445.sabcs19-p5-01-07
Cited by 6

Related Papers

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k